Open AccessComplement‐Dependent Cytotoxicity (CDC) to Detect Anti‐HLA Antibodies: Old but Gold
Author(s) -
Saito Patrícia Keiko,
Yamakawa Roger Haruki,
Silva Pereira Lucieni Christina Marques,
Silva Junior Waldir Veríssimo,
Borelli Sueli Donizete
Publication year - 2014
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.21678
Subject(s) - complement dependent cytotoxicity , antibody , human leukocyte antigen , panel reactive antibody , cytotoxicity , immunoassay , dithiothreitol , immunology , chemistry , antigen , microbiology and biotechnology , medicine , biology , in vitro , antibody dependent cell mediated cytotoxicity , monoclonal antibody , biochemistry , enzyme
Background The criterion (gold) standard to detect anti‐human leukocyte antigen (HLA) antibodies is the complement‐dependent cytotoxicity (CDC) assay. Recently, more sensitive methods have been used for the same purpose. Methods This study analyzed 70 serum samples of patients with end‐stage renal disease using CDC, CDC with the addition of anti‐human globulin (CDC‐AHG), CDC with the addition of dithiothreitol (CDC‐DTT), and the recent solid‐phase immunoassay (SPI; Labscreen PRA) to detect anti‐HLA antibodies. Results Mean percent panel reactive antibodies (PRA) detected by SPI was 37.5% (±34.2) higher than the values detected by the other methods. Comparative analyses revealed significant difference between CDC and CDC‐AHG, and between CDC and SPI ( P < 0.0001), but not between CDC‐AHG and SPI ( P = 0.8026). Conclusion Although the CDC‐AHG method is “old,” its performance to detect anti‐HLA antibodies in the samples analyzed was comparable to the SPI in the evaluation of percent class I PRA.